WO2001087329A8 - Liquid pharmaceutical composition containing an erythropoietin derivate - Google Patents

Liquid pharmaceutical composition containing an erythropoietin derivate

Info

Publication number
WO2001087329A8
WO2001087329A8 PCT/EP2001/005187 EP0105187W WO0187329A8 WO 2001087329 A8 WO2001087329 A8 WO 2001087329A8 EP 0105187 W EP0105187 W EP 0105187W WO 0187329 A8 WO0187329 A8 WO 0187329A8
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
liquid pharmaceutical
erythropoietin
derivate
composition containing
Prior art date
Application number
PCT/EP2001/005187
Other languages
French (fr)
Other versions
WO2001087329A1 (en
Inventor
Apollon Papadimitriou
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8168722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2001087329(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to NZ522030A priority Critical patent/NZ522030A/en
Priority to DE60109625.8T priority patent/DE60109625T3/en
Priority to AT01943331T priority patent/ATE291436T2/en
Priority to EP01943331.7A priority patent/EP1311285B2/en
Priority to KR1020027015429A priority patent/KR100758044B1/en
Priority to MEP-2008-907A priority patent/ME00673B/en
Priority to PL361341A priority patent/PL219131B1/en
Priority to AU65934/01A priority patent/AU784091B2/en
Priority to KR1020077003371A priority patent/KR20070032815A/en
Priority to CA2408685A priority patent/CA2408685C/en
Priority to DK01943331.7T priority patent/DK1311285T4/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Priority to BRPI0110914A priority patent/BRPI0110914B8/en
Priority to IL15265901A priority patent/IL152659A0/en
Priority to JP2001583796A priority patent/JP3967594B2/en
Priority to ES01943331.7T priority patent/ES2237574T5/en
Priority to MXPA02011303A priority patent/MXPA02011303A/en
Priority to HU0302114A priority patent/HU230874B1/en
Priority to PT01943331T priority patent/PT1311285E/en
Priority to SI200130331T priority patent/SI1311285T1/xx
Publication of WO2001087329A1 publication Critical patent/WO2001087329A1/en
Publication of WO2001087329A8 publication Critical patent/WO2001087329A8/en
Priority to IL152659A priority patent/IL152659A/en
Priority to HR20020880A priority patent/HRP20020880B1/en
Priority to NO20025450A priority patent/NO330934B1/en
Priority to HK03109033A priority patent/HK1056683A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Abstract

The present invention relates to a liquid pharmaceutical composition comprising an erythropoietin protein, a multiple charged inorganic anion in a pharmaceutically acceptable buffer suitable to keep the solution pH in the range from about 5.5 to about 7.0, and optionally one or more pharmaceutically acceptable excipients. This composition is especially useful for the prophylaxis and treatment of diseases related to erythropoiesis.
PCT/EP2001/005187 2000-05-15 2001-05-08 Liquid pharmaceutical composition containing an erythropoietin derivate WO2001087329A1 (en)

Priority Applications (23)

Application Number Priority Date Filing Date Title
BRPI0110914A BRPI0110914B8 (en) 2000-05-15 2001-05-08 'liquid pharmaceutical composition, process for its preparation and use of a pharmaceutical composition'
IL15265901A IL152659A0 (en) 2000-05-15 2001-05-08 Pharmaceutical composition
DE60109625.8T DE60109625T3 (en) 2000-05-15 2001-05-08 LIQUID MEDICINE PREPARATION CONTAINING AN ERYTHROPOIETIN DERIVATIVE
JP2001583796A JP3967594B2 (en) 2000-05-15 2001-05-08 New pharmaceutical composition
KR1020027015429A KR100758044B1 (en) 2000-05-15 2001-05-08 New pharmaceutical composition
MEP-2008-907A ME00673B (en) 2000-05-15 2001-05-08 New pharmaceutical composition
PL361341A PL219131B1 (en) 2000-05-15 2001-05-08 Novel pharmaceutical composition
AU65934/01A AU784091B2 (en) 2000-05-15 2001-05-08 New pharmaceutical composition
KR1020077003371A KR20070032815A (en) 2000-05-15 2001-05-08 New pharmaceutical composition
CA2408685A CA2408685C (en) 2000-05-15 2001-05-08 Liquid pharmaceutical composition containing an erythropoietin derivate
DK01943331.7T DK1311285T4 (en) 2000-05-15 2001-05-08 Liquid pharmaceutical composition containing an erythropoietin derivative
NZ522030A NZ522030A (en) 2000-05-15 2001-05-08 Erythropoietin composition with a multiple charged inorganic anion i.e. a sulfate a citrate or a phosphate to stabilize the composition
SI200130331T SI1311285T1 (en) 2000-05-15 2001-05-08
AT01943331T ATE291436T2 (en) 2000-05-15 2001-05-08 LIQUID MEDICINAL PREPARATION CONTAINING AN ERYTHROPOIETIN DERIVATIVE
EP01943331.7A EP1311285B2 (en) 2000-05-15 2001-05-08 Liquid pharmaceutical composition containing an erythropoietin derivative
ES01943331.7T ES2237574T5 (en) 2000-05-15 2001-05-08 Liquid pharmaceutical composition containing an erythropoietin derivative
MXPA02011303A MXPA02011303A (en) 2000-05-15 2001-05-08 Liquid pharmaceutical composition containing an erythropoietin derivate.
HU0302114A HU230874B1 (en) 2000-05-15 2001-05-08 Liquid pharmaceutical compositions stable at room temperature which comprising a pegylated human erythropoietin protein
PT01943331T PT1311285E (en) 2000-05-15 2001-05-08 Liquid pharmaceutical composition containing a derivative of erythropoietin
IL152659A IL152659A (en) 2000-05-15 2002-11-05 Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer
HR20020880A HRP20020880B1 (en) 2000-05-15 2002-11-07 New pharmaceutical composition
NO20025450A NO330934B1 (en) 2000-05-15 2002-11-14 Liquid pharmaceutical composition and its use and preparation.
HK03109033A HK1056683A1 (en) 2000-05-15 2003-12-11 New pharmaceutical composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00110355 2000-05-15
EP00110355.5 2000-05-15

Publications (2)

Publication Number Publication Date
WO2001087329A1 WO2001087329A1 (en) 2001-11-22
WO2001087329A8 true WO2001087329A8 (en) 2002-03-07

Family

ID=8168722

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/005187 WO2001087329A1 (en) 2000-05-15 2001-05-08 Liquid pharmaceutical composition containing an erythropoietin derivate

Country Status (36)

Country Link
US (2) US7169754B2 (en)
EP (2) EP1525889A1 (en)
JP (1) JP3967594B2 (en)
KR (3) KR20070032815A (en)
CN (1) CN1309416C (en)
AR (2) AR035034A1 (en)
AT (1) ATE291436T2 (en)
AU (1) AU784091B2 (en)
BR (1) BRPI0110914B8 (en)
CA (1) CA2408685C (en)
CZ (1) CZ304855B6 (en)
DE (1) DE60109625T3 (en)
DK (1) DK1311285T4 (en)
EC (2) ECSP024352A (en)
ES (1) ES2237574T5 (en)
HK (1) HK1056683A1 (en)
HR (1) HRP20020880B1 (en)
HU (1) HU230874B1 (en)
IL (2) IL152659A0 (en)
JO (1) JO3404B1 (en)
MA (1) MA26901A1 (en)
ME (1) ME00673B (en)
MX (1) MXPA02011303A (en)
MY (1) MY128654A (en)
NO (1) NO330934B1 (en)
NZ (1) NZ522030A (en)
PE (1) PE20020050A1 (en)
PL (1) PL219131B1 (en)
PT (1) PT1311285E (en)
RS (1) RS51292B (en)
RU (1) RU2281116C2 (en)
SI (1) SI1311285T1 (en)
TW (2) TWI288644B (en)
UY (1) UY26704A1 (en)
WO (1) WO2001087329A1 (en)
ZA (1) ZA200208500B (en)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (en) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US5545553A (en) * 1994-09-26 1996-08-13 The Rockefeller University Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
US7304150B1 (en) * 1998-10-23 2007-12-04 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
CZ299516B6 (en) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Erythropoietin glycoprotein conjugate, process for its preparation and use and pharmaceutical composition containing thereof
EP1274720A4 (en) * 2000-04-12 2004-08-18 Human Genome Sciences Inc Albumin fusion proteins
NZ522030A (en) * 2000-05-15 2004-11-26 F Erythropoietin composition with a multiple charged inorganic anion i.e. a sulfate a citrate or a phosphate to stabilize the composition
ATE505204T1 (en) * 2000-12-20 2011-04-15 Hoffmann La Roche CONJUGATES OF ERYTHROPOIETIN (EPO) WITH POLYETHYLENE GLYCOL (PEG)
KR100645843B1 (en) 2000-12-20 2006-11-14 에프. 호프만-라 로슈 아게 Erythropoietin conjugates
FR2823220B1 (en) * 2001-04-04 2003-12-12 Genodyssee NOVEL ERYTHROPOIETIN (EPO) POLYNUCLEOTIDES AND POLYPEPTIDES
WO2002097038A2 (en) * 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
US20030104996A1 (en) * 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
JP2003152145A (en) * 2001-08-31 2003-05-23 Sumitomo Electric Ind Ltd Semiconductor heat dissipating substrate, method for its manufacture, and package
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
AU2004236174B2 (en) * 2001-10-10 2011-06-02 Novo Nordisk A/S Glycopegylation methods and proteins/peptides produced by the methods
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7399613B2 (en) * 2001-10-10 2008-07-15 Neose Technologies, Inc. Sialic acid nucleotide sugars
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7795210B2 (en) * 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7179617B2 (en) * 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US7473680B2 (en) 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
EP2277888A3 (en) * 2001-12-21 2011-04-27 Human Genome Sciences, Inc. Fusion proteins of albumin and erythropoietin
EP1463752A4 (en) * 2001-12-21 2005-07-13 Human Genome Sciences Inc Albumin fusion proteins
DE60336555D1 (en) * 2002-06-21 2011-05-12 Novo Nordisk Healthcare Ag PEGYLATED GLYCO FORMS OF FACTOR VII
SI21258A (en) * 2002-07-17 2004-02-29 LEK farmacevtska dru�ba d.d. Stable pharmaceutical preparation containing erythropoietin and poloxamer polyol
US7459435B2 (en) 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
CN101371920A (en) * 2002-09-09 2009-02-25 沃伦药品公司 Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
US7470779B2 (en) * 2002-09-20 2008-12-30 Pfizer Inc. Process for decreasing aggregate levels of pegylated protein
US7459436B2 (en) 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
CA2519092C (en) * 2003-03-14 2014-08-05 Neose Technologies, Inc. Branched water-soluble polymers and their conjugates
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
EP1613261A4 (en) * 2003-04-09 2011-01-26 Novo Nordisk As Intracellular formation of peptide conjugates
ES2380093T3 (en) * 2003-05-09 2012-05-08 Biogenerix Ag Compositions and methods for the preparation of human growth hormone glycosylation mutants
WO2004100997A2 (en) * 2003-05-12 2004-11-25 Affymax, Inc. Spacer moiety for poly(ethylene glycol) -modified peptides
OA13164A (en) * 2003-05-12 2006-12-13 Affymax Inc Novel peptides that bind to the erythropoietin receptor.
MXPA05012315A (en) * 2003-05-12 2006-04-18 Affymax Inc Novel poly(ethylene glycol) modified compounds and uses thereof.
KR101227666B1 (en) * 2003-05-12 2013-01-31 아피맥스, 인크. Peptides that bind to the erythropoietin receptor
NZ543859A (en) 2003-06-10 2008-01-31 Lg Life Sciences Ltd Aqueous formulation that has storage stability over a long period without serum albumin comprising human erythropoietin; non-ionic surfactant, polyhydric alcohol, neutral amino acid and sugar alcohol as stabilizers
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) * 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
ES2445948T3 (en) * 2003-11-24 2014-03-06 Ratiopharm Gmbh Glycopegylated Erythropoietin
US7842661B2 (en) * 2003-11-24 2010-11-30 Novo Nordisk A/S Glycopegylated erythropoietin formulations
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
NZ547554A (en) * 2003-12-03 2009-09-25 Biogenerix Ag Glycopegylated granulocyte colony stimulating factor
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
US20080318850A1 (en) * 2003-12-03 2008-12-25 Neose Technologies, Inc. Glycopegylated Factor Ix
WO2005058347A1 (en) 2003-12-19 2005-06-30 F. Hoffmann-La Roche Ag Use of erythropoietin in the treatment of disturbances of iron distribution in chronic inflammatory intestinal diseases
CN101072789B (en) * 2004-01-08 2013-05-15 生物种属学股份公司 O-linked glycosylation of peptides
WO2005074524A2 (en) * 2004-02-02 2005-08-18 Ambrx, Inc. Modified human interferon polypeptides and their uses
DE202004020676U1 (en) * 2004-03-10 2005-11-10 Bioceuticals Arzneimittel Ag Storage-stable liquid erythropoietin formulation, for treatment of renal insufficiency, comprises specified amino acids but no preservatives, urea or albumen and is not a reconstituted lyophilizate
US20050282751A1 (en) * 2004-03-19 2005-12-22 Ajinomoto Co., Inc. Therapeutic agent for renal anemia
EP1726303A4 (en) * 2004-03-19 2011-03-02 Ajinomoto Kk Therapeutic agent for renal anemia
EA010889B1 (en) * 2004-03-26 2008-12-30 Янссен Фармацевтика Н.В. Combination dosing regimen for erythropoetin
AR049580A1 (en) * 2004-07-07 2006-08-16 Lundbeck & Co As H CARBAMILATED EPO AND METHOD FOR YOUR PRODUCTION
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
US20090292110A1 (en) * 2004-07-23 2009-11-26 Defrees Shawn Enzymatic modification of glycopeptides
US20060029551A1 (en) * 2004-08-05 2006-02-09 Kui Liu Stable particle formulations of erythropoietin receptor agonists
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
EP1799249A2 (en) * 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegylated interferon alpha
EP1814573B1 (en) * 2004-10-29 2016-03-09 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
JP2006137678A (en) * 2004-11-10 2006-06-01 Shionogi & Co Ltd Interleukin-2 composition
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
EA200700990A1 (en) * 2004-11-11 2008-04-28 Афимакс, Инк. NEW PEPTIDES THAT BIND THE ERYTHROPOIETIN RECEPTOR
US20100009902A1 (en) * 2005-01-06 2010-01-14 Neose Technologies, Inc. Glycoconjugation Using Saccharyl Fragments
NZ556436A (en) 2005-01-10 2010-11-26 Biogenerix Ag Glycopegylated granulocyte colony stimulating factor
EP1844068A4 (en) * 2005-01-25 2009-09-30 Apollo Life Sciences Ltd Molecules and chimeric molecules thereof
WO2006105426A2 (en) * 2005-03-30 2006-10-05 Neose Technologies, Inc. Manufacturing process for the production of peptides grown in insect cell lines
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US20070037886A1 (en) * 2005-04-26 2007-02-15 Ajinomoto Co., Inc. Bone marrow erythroid progenitor cell(s) differentiation inducer
US20110003744A1 (en) * 2005-05-25 2011-01-06 Novo Nordisk A/S Glycopegylated Erythropoietin Formulations
JP5216580B2 (en) 2005-05-25 2013-06-19 ノヴォ ノルディスク アー／エス Glycopegylated factor IX
US7550433B2 (en) * 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
AU2006295340B2 (en) 2005-08-05 2010-11-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
US20090305967A1 (en) * 2005-08-19 2009-12-10 Novo Nordisk A/S Glycopegylated factor vii and factor viia
US20070105755A1 (en) * 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20070072795A1 (en) * 2005-09-28 2007-03-29 Anton Haselbeck Treatment of neurodegenerative disorders
US20090048440A1 (en) * 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
CN105001320A (en) 2005-11-23 2015-10-28 阿塞勒隆制药公司 Activin-ActRIIa antagonists and uses for promoting bone growth
CN101015684B (en) * 2006-02-10 2011-08-24 华北制药集团新药研究开发有限责任公司 Recombinant erythropoietin liquor preparation
JP5553506B2 (en) * 2006-03-22 2014-07-16 中外製薬株式会社 Erythropoietin solution formulation
JP2009544327A (en) * 2006-07-21 2009-12-17 ノヴォ ノルディスク アー／エス Glycosylation of peptides with O-linked glycosylation sequences
CA2659990C (en) * 2006-08-04 2016-03-22 Prolong Pharmaceuticals, Inc. Polyethylene glycol erythropoietin conjugates
JP2010505874A (en) 2006-10-03 2010-02-25 ノヴォ ノルディスク アー／エス Purification method for polypeptide conjugates
LT2068907T (en) * 2006-10-04 2018-01-10 Novo Nordisk A/S Glycerol linked pegylated sugars and glycopeptides
US20080207487A1 (en) * 2006-11-02 2008-08-28 Neose Technologies, Inc. Manufacturing process for the production of polypeptides expressed in insect cell-lines
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
TW201940502A (en) 2007-02-02 2019-10-16 美商艾瑟勒朗法瑪公司 Variants derived from ActRIIB and uses therefor
KR20150064246A (en) 2007-04-03 2015-06-10 바이오제너릭스 게엠베하 Methods of treatment using glycopegylated g―csf
US20090053167A1 (en) * 2007-05-14 2009-02-26 Neose Technologies, Inc. C-, S- and N-glycosylation of peptides
US20080286341A1 (en) * 2007-05-16 2008-11-20 Sven-Borje Andersson Buffered coated nicotine containing products
EP2162535A4 (en) * 2007-06-04 2011-02-23 Novo Nordisk As O-linked glycosylation using n-acetylglucosaminyl transferases
JP5876649B2 (en) 2007-06-12 2016-03-02 ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ Improved process for producing nucleotide sugars
EP2170268A2 (en) * 2007-06-25 2010-04-07 Amgen, Inc. Compositions of specific binding agents to hepatocyte growth factor
US7968811B2 (en) * 2007-06-29 2011-06-28 Harley-Davidson Motor Company Group, Inc. Integrated ignition and key switch
CL2008002054A1 (en) 2007-07-17 2009-05-29 Hoffmann La Roche Method for the regeneration of a cation exchange chromatography column after elusion of monopeglated erythropoietin and method to obtain a monopeglated erythropoietin, incorporating the regeneration method of the cation exchange column.
AR067537A1 (en) 2007-07-17 2009-10-14 Hoffmann La Roche PURIFIED POLYPEPTIDES PURIFICATION
NZ583276A (en) 2007-08-27 2012-06-29 Biogenerix Ag Liquid formulations of granulocyte colony stimulating factor and polymer conjugates
US8207112B2 (en) * 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
CN101456911A (en) * 2007-12-12 2009-06-17 江苏豪森药业股份有限公司 Erythrocyte-stimulating factor mimic peptide derivative, medical salts thereof, preparation method and use thereof
WO2009089396A2 (en) * 2008-01-08 2009-07-16 Neose Technologies, Inc. Glycoconjugation of polypeptides using oligosaccharyltransferases
CN103497246B (en) 2008-02-27 2016-08-10 诺沃—诺迪斯克有限公司 The Factor VlII molecule puted together
PT3750552T (en) 2008-08-14 2023-06-28 Acceleron Pharma Inc Gdf traps
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
US20120172299A1 (en) * 2008-09-23 2012-07-05 F. Hoffmann-La Roche Ag Purification of erythropoietin
AU2010258931B2 (en) 2009-06-08 2015-04-23 Acceleron Pharma Inc. Methods for increasing thermogenic adipocytes
MX2011013364A (en) 2009-06-12 2012-03-16 Acceleron Pharma Inc Truncated actriib-fc fusion proteins.
US8357301B2 (en) 2009-06-24 2013-01-22 Hoffmann-La Roche, Inc. Chromatography equipment characterization
BRPI0902481B8 (en) 2009-07-31 2021-05-25 Soc Beneficente De Senhoras Hospital Sirio Libanes pharmaceutical composition comprising hemopressin and its use.
CN113577291A (en) * 2009-08-13 2021-11-02 阿塞勒隆制药公司 Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels
US20120264688A1 (en) * 2009-09-23 2012-10-18 Walter Hinderer Process for the purification of recombinant human erythropoietin (epo), epo thus purified and pharmaceutical compositions comprising same
JP6267425B2 (en) 2009-11-17 2018-01-24 アクセルロン ファーマ， インコーポレイテッド ACTRIIB protein and its variants and uses thereof for utrophin induction for the treatment of muscular dystrophy
SG190891A1 (en) 2010-12-21 2013-07-31 Hoffmann La Roche Chromatography equipment characterization
AR094821A1 (en) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd LIQUID FORMULATION OF AN INSULINOTROPIC PEPTIDE CONJUGATE OF PROLONGED ACTION
CN102816227A (en) * 2012-08-30 2012-12-12 深圳赛保尔生物药业有限公司 Erythropoietin recovery method
KR102279522B1 (en) 2012-11-02 2021-07-19 셀진 코포레이션 Activin-actrii antagonists and uses for treating bone and other disorders
CU20140003A7 (en) 2014-01-08 2015-08-27 Ct De Inmunología Molecular Biofarmacuba CONJUGATE UNDERSTANDING ERYTHROPOYETIN AND A RAMIFIED POLYMER STRUCTURE
US10052361B2 (en) 2014-03-29 2018-08-21 Intas Pharmaceuticals Ltd Liquid pharmaceutical composition of conjugated erythropoietin
TN2016000553A1 (en) 2014-06-13 2018-04-04 Acceleron Pharma Inc Methods and compositions for treating ulcers
US11608357B2 (en) 2018-08-28 2023-03-21 Arecor Limited Stabilized antibody protein solutions
EP3372242A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
EP3372241A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
WO2018184692A1 (en) * 2017-04-07 2018-10-11 Ares Trading S.A. Liquid pharmaceutical composition
CN111727063A (en) * 2017-12-29 2020-09-29 豪夫迈·罗氏有限公司 Methods for providing pegylated protein compositions
CN111558046A (en) * 2020-05-27 2020-08-21 华润昂德生物药业有限公司 Application of trehalose in preparation of recombinant human erythropoietin liquid preparation, preparation method and application
TWI740635B (en) * 2020-09-09 2021-09-21 財團法人工業技術研究院 Polyvinylidene fluoride film composition, and polyvinylidene fluoride isolation film

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US147431A (en) * 1874-02-10 Improvement in game boards
US115833A (en) * 1871-06-13 Improvement in grain-driers
JPS6197229A (en) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd Stable erythropoietin preparation
US4732889A (en) * 1985-02-06 1988-03-22 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of rheumatoid arthritis
DE3729863A1 (en) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh STABILIZED ERYTHROPOIETIN LYOPHILISATES
DE3734923C1 (en) * 1987-10-15 1989-01-26 Biotest Pharma Gmbh Process for the preparation of a sterile plasma protein solution containing fibrinogen and coagulation factor XIII
DE4014654A1 (en) 1990-05-08 1991-11-14 Behringwerke Ag GALENIC AQUEOUS FORMULATIONS OF ERYTHROPOIETIN AND THEIR USE
JPH05502463A (en) * 1990-09-28 1993-04-28 オーソ・フアーマシユーチカル・コーポレーシヨン hybrid growth factor
US5272135A (en) * 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
NZ244778A (en) 1991-10-21 1994-03-25 Ortho Pharma Corp Peg imidates and protein derivatives thereof
US5460944A (en) * 1991-10-28 1995-10-24 Boehringer Mannheim Gmbh Storable protein solution
DE4135542A1 (en) 1991-10-28 1993-04-29 Boehringer Mannheim Gmbh STORAGE PROTEIN SOLUTIONS
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
US5354934A (en) † 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
AU7097094A (en) 1993-06-01 1994-12-20 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
CN1057534C (en) * 1993-08-17 2000-10-18 柯瑞英-艾格公司 Erythropoietin analogs
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
TWI240627B (en) * 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
CA2262994A1 (en) † 1996-08-02 1998-02-12 Ortho-Mcneil Pharmaceutical, Inc. Polypeptides having a single covalently bound n-terminal water-soluble polymer
US5919656A (en) * 1996-11-15 1999-07-06 Amgen Canada Inc. Genes encoding telomerase protein 1
EP0885613A1 (en) * 1997-06-21 1998-12-23 Roche Diagnostics GmbH Use of modified hemoglobins for treatment of anemias and erythropoietin and modified hemoglobin containing combined preparations
DE19734293A1 (en) * 1997-08-08 1999-02-11 Boehringer Mannheim Gmbh Use of pharmaceutical combination preparations containing erythropoietin and iron preparations for the treatment of rheumatic diseases
HU228492B1 (en) 1998-10-23 2013-03-28 Amgen Inc Methods and compositions for the prevention and treatment of anemia
UY25790A1 (en) 1998-11-06 2000-08-21 Bio Sidus S A PHARMACEUTICAL FORMS OF RECOMBINANT HUMAN ERYTHROPOYETIN STABLE AT ROOM TEMPERATURE AND SUITABLE FOR USE IN HUMANS, FORMULATIONS AND FREEZE PROCEDURES FOR THEIR OBTAINING.
JP2000247903A (en) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd Long-term stabilized pharmaceutical preparation
DK1181036T3 (en) * 1999-04-09 2008-11-24 Ortho Mcneil Pharm Inc Pharmaceutical Compositions of Erythropoietin
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
JO2291B1 (en) * 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythopintin derivatives
CZ299516B6 (en) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Erythropoietin glycoprotein conjugate, process for its preparation and use and pharmaceutical composition containing thereof
NZ516735A (en) 1999-07-22 2004-01-30 Aventis Pharma Inc Multi-dose erythropoietin formulations containing benzethonium chloride as a preservative
WO2001017542A1 (en) † 1999-09-08 2001-03-15 Chugai Seiyaku Kabushiki Kaisha Protein solution preparation and method of stabilizing the same
JP4683810B2 (en) * 2000-02-29 2011-05-18 中外製薬株式会社 Long-term stabilized preparation
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
NZ522030A (en) * 2000-05-15 2004-11-26 F Erythropoietin composition with a multiple charged inorganic anion i.e. a sulfate a citrate or a phosphate to stabilize the composition
JP5490972B2 (en) † 2000-08-04 2014-05-14 中外製薬株式会社 Protein injection formulation
KR100645843B1 (en) * 2000-12-20 2006-11-14 에프. 호프만-라 로슈 아게 Erythropoietin conjugates
US20030104996A1 (en) * 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US6818613B2 (en) * 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins

Also Published As

Publication number Publication date
DE60109625T2 (en) 2006-03-30
PL219131B1 (en) 2015-03-31
EP1311285A2 (en) 2003-05-21
ECSP024352A (en) 2003-03-31
IL152659A0 (en) 2003-06-24
CA2408685A1 (en) 2001-11-22
RU2281116C2 (en) 2006-08-10
AR035034A1 (en) 2004-04-14
BRPI0110914B1 (en) 2016-03-01
JP2003533487A (en) 2003-11-11
JO3404B1 (en) 2019-10-20
HUP0302114A2 (en) 2003-10-28
AU784091B2 (en) 2006-02-02
DK1311285T3 (en) 2005-06-27
BRPI0110914B8 (en) 2021-05-25
DE60109625D1 (en) 2005-04-28
NO330934B1 (en) 2011-08-22
MEP90708A (en) 2011-12-20
RS51292B (en) 2010-12-31
CZ304855B6 (en) 2014-12-10
KR100758044B1 (en) 2007-09-11
BR0110914A (en) 2003-02-11
CN1309416C (en) 2007-04-11
AR092919A2 (en) 2015-05-06
KR20070032815A (en) 2007-03-22
ZA200208500B (en) 2004-01-28
US20020037841A1 (en) 2002-03-28
HK1056683A1 (en) 2004-02-27
MXPA02011303A (en) 2003-04-25
ECSP10004352A (en) 2011-01-31
MY128654A (en) 2007-02-28
IL152659A (en) 2010-12-30
WO2001087329A1 (en) 2001-11-22
JP3967594B2 (en) 2007-08-29
MA26901A1 (en) 2004-12-20
TWI288644B (en) 2007-10-21
CZ20024005A3 (en) 2004-01-14
KR20050121762A (en) 2005-12-27
SI1311285T1 (en) 2005-08-31
US7169754B2 (en) 2007-01-30
HRP20020880B1 (en) 2006-04-30
ATE291436T2 (en) 2005-04-15
AU6593401A (en) 2001-11-26
HU230874B1 (en) 2018-11-29
YU83502A (en) 2005-11-28
NO20025450L (en) 2002-11-14
DE60109625T3 (en) 2017-08-03
HRP20020880A2 (en) 2004-12-31
US7202208B2 (en) 2007-04-10
CA2408685C (en) 2011-02-01
US20040147431A1 (en) 2004-07-29
PT1311285E (en) 2005-06-30
KR20030001509A (en) 2003-01-06
HUP0302114A3 (en) 2012-12-28
EP1311285B1 (en) 2005-03-23
UY26704A1 (en) 2001-12-28
PL361341A1 (en) 2004-10-04
ME00673B (en) 2011-12-20
NO20025450D0 (en) 2002-11-14
EP1311285B2 (en) 2017-04-12
NZ522030A (en) 2004-11-26
ES2237574T5 (en) 2017-08-09
TWI288643B (en) 2007-10-21
CN1429116A (en) 2003-07-09
PE20020050A1 (en) 2002-02-01
ES2237574T3 (en) 2005-08-01
EP1525889A1 (en) 2005-04-27
DK1311285T4 (en) 2017-07-24

Similar Documents

Publication Publication Date Title
WO2001087329A8 (en) Liquid pharmaceutical composition containing an erythropoietin derivate
WO2001098290A3 (en) Thiophene derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
BR0109650A (en) 3-cyanoquinolines, 3-cyano-1,6-naphthyridines and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
WO2002047715A3 (en) Compositions of peptide crystals
CA2319308A1 (en) Pharmaceutical agents
MXPA04000920A (en) Aminoisoxazole derivatives active as kinase inhibitors.
EP1820503A3 (en) Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
BG101118A (en) Therapeutical compounds
PL374325A1 (en) Succinic acid salts of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9 ]-hexadeca-2(11),3,5,7,9,-pentaene and pharmaceutical compositions thereof
MXPA05003253A (en) Novel pyrimidineamide derivatives and the use thereof.
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
WO2001034641A8 (en) Antimicrobial activity of the first cationic cluster of human lactoferrin
WO2003051838A3 (en) Protein kinase inhibitors
CA2420640A1 (en) Combination preparations of 3-n-formyl hydroxy amino propyl phosphonic acid derivatives or 3-n-acetyl hydroxy amino propyl phosphonic acid derivatives together with special pharmaceutical active ingredients
MXPA02011533A (en) NOVEL FORMULATIONS OF agr; 2, 4 DISULFOPHENYL N TERT BUTYLNITRONE.
UA66932C2 (en) Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine
CA2429793A1 (en) Interferon therapeutic effect enhancer
EP0743068A3 (en) Composition for inhibiting bone loss containing vanadyl sulfate
CA2387600A1 (en) Novel fusidic acid derivatives
WO2002070537A3 (en) Fusidic acid derivatives
AU5494298A (en) Pharmaceutical compositions for the treatment of the eye
IL160160A0 (en) SUBSTITUTED 5,6,6a, 11b-TETRAHYDRO-7-OXA-5-AZA-BENZO[c]FLUORENE-6-CARBOXYLIC ACID DERIVATIVES SERVING AS NMDA ANTAGONISTS
WO2003040119A8 (en) Angiogenesis inhibitors
WO1999019324A3 (en) Antipsychotic substituted piperidine derivatives
WO2002100342A3 (en) (s, s'), (s, r')-amphetaminil, compositions and uses thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-835/02

Country of ref document: YU

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CO CU CZ DE DK EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CO CU CZ DE DK EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page

Free format text: REVISED TITLE RECEIVED BY THE INTERNATIONAL BUREAU AFTER COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION

WWE Wipo information: entry into national phase

Ref document number: 522030

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2002/08500

Country of ref document: ZA

Ref document number: 200208500

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 152659

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 65934/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: P20020880A

Country of ref document: HR

Ref document number: 2001943331

Country of ref document: EP

Ref document number: IN/PCT/2002/1827/CHE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2408685

Country of ref document: CA

Ref document number: 02102350

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/011303

Country of ref document: MX

Ref document number: 1020027015429

Country of ref document: KR

Ref document number: 018095607

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: PV2002-4005

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 2002133236

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020027015429

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001943331

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2002-4005

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 522030

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 522030

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2001943331

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1020027015429

Country of ref document: KR